Studies highlight importance of comprehensive genomic profiling to better treat breast cancer
IRVING, Texas, December 7, 2022 – Caris Life Sciences® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that it will present findings at the San Antonio Breast Cancer Symposium (SABCS) that illustrate the potential impact of molecular profiling on the treatment of breast cancer. SABCS is being held December 6-10, 2022 in San Antonio, Texas.
Presentations and posters from Caris include:
“Our data at SABCS 2022 emphasizes Caris Life Sciences’ contributions to increasing our understanding of the rapidly-emerging area of HER2-low as a target for antibody-drug conjugates,” said Dr. Sledge. “As precision oncology continues to evolve, our cutting-edge work on tumor biology and molecular biomarkers will have broad implications in helping to guide treatment decisions and the development of novel therapeutic options for patients across a range of tumor types, including breast cancer.”
Human epidermal growth factor receptor 2 (HER2)-low is a newly defined subset of HER2-negative breast cancer that has been reported to account for up to half of all breast cancer cases. The molecular landscape of HER2-low compared to historical subtypes was investigated across 19,789 breast cancer samples using Caris’ Next-Generation Sequencing (NGS) technology.
Study results demonstrate that when HER2-low breast cancer is stratified by hormone receptor (HR) status, it shares common genomic features with classically defined subsets of HR+ or HRneg disease. When HR+/Her2-low tumors were compared with triple negative breast cancer, significant differences were observed in PIK3CA (an actionable mutation) and TP53 (a prognostic alteration) and warrant further assessment. These findings advance understanding of the molecular landscape of HER2-low breast cancer which has recently become a new entity for treatment. This knowledge is key to understanding the clinical and biological factors driving treatment resistance and how these factors can impact post-progression treatment options in HER2-low breast cancer.
“Caris’ Precision Oncology Alliance (POA) continues its contribution to advancing breast cancer research by presenting novel findings on the molecular features of HER2-low breast cancer at this year’s SABCS,” said Chadi Nabhan, M.D., MBA, FACP, Chairman of the Caris Precision Oncology Alliance. “By leveraging Caris’ expansive real-world clinico-genomic database, our partner academic institutions are able to uncover new insights into the underpinnings of breast cancer biology and clinical outcomes.”
The POA includes 75 cancer centers and academic institutions, including 34 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients.
Additional Presentations Reveal Potential Impact of Comprehensive Molecular Profiling
Caris will present additional data from studies demonstrating the critical role of precision medicine and molecular profiling in the treatment of breast cancer. All presentations will be made available online through Caris’ website beginning December 7.
About Caris Life Sciences
Caris Life Sciences® (Caris) is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale clinico-genomic database and cognitive computing needed to analyze and unravel the molecular complexity of disease. This information provides an unmatched resource and the ideal path forward to conduct the basic, fundamental research to accelerate discovery for detection, diagnosis, monitoring, therapy selection and drug development to improve the human condition.
With a primary focus on cancer, Caris’ suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. Caris’ latest advancement is a blood-based, circulating nucleic acids sequencing (cNAS) assay that combines comprehensive molecular analysis (Whole Exome and Whole Transcriptome Sequencing from blood) and serial monitoring – making it the most powerful liquid biopsy assay ever developed.
Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Denver, Tokyo, Japan and Basel, Switzerland. Caris provides services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit CarisLifeSciences.com or follow us on LinkedIn.